Atak Ramazan, Turhan Hasan, Senen Kubilay, Yalta Kenan, Ayaz Selime, Alyan Omer, Basar Nurcan, Demirkan Deniz
Department of Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey.
J Heart Valve Dis. 2004 Mar;13(2):159-64.
Systemic thromboembolism is a major complication in patients with mitral stenosis (MS), especially in those who have atrial fibrillation (AF). It has been suggested that systemic coagulation activity may be increased in these patients. The study aim was to investigate the relationship between control of ventricular rate and systemic coagulation factors in patients with MS and AF by measuring plasma levels of prothrombin fragment (PF) 1+2, thrombin-antithrombin III complex (TAT) and plasminogen activator inhibitor-1.
Fifty-four consecutive patients with moderate to severe MS and AF were included in the study. Patients with resting heart rates < 100 beats per min were considered as having a controlled ventricular response rate (group A; n = 28) and those with > 100 beats per min as an uncontrolled ventricular response rate (group B; n = 26).
Group A patients had a lower mean mitral gradient and pulmonary artery pressure than group B patients (11 +/- 6 versus 15 +/- 5 and 35 +/- 7 versus 39 +/- 8; p < 0.05, respectively). Plasma concentrations of PF 1+2 (4.17 +/- 2.1 versus 2.95 +/- 1.21; p < 0.01) and TAT III (4.61 +/- 1.75 versus 3.12 +/- 1.01; p < 0.01) were elevated in group B compared with group A. Similarly, group B patients had higher plasminogen activator inhibitor-1 levels than group A patients (7.87 +/- 3.8 versus 5.8 +/- 2.9; p < 0.05). A significant correlation was found between heart rate and plasma PF 1+2 and TAT levels. Multiple logistic regression analysis revealed that heart rate and mean mitral gradient were independent predictors of systemic coagulation activation.
Besides contributing towards hemodynamic and symptomatic relief, the control of AF rate in MS patients induces a drastic decline in coagulation activation, and may also reduce the incidence of thromboembolism.
系统性血栓栓塞是二尖瓣狭窄(MS)患者的主要并发症,尤其是合并心房颤动(AF)的患者。有研究表明,这些患者的全身凝血活性可能会增强。本研究旨在通过检测血浆凝血酶原片段(PF)1+2、凝血酶-抗凝血酶III复合物(TAT)和纤溶酶原激活物抑制剂-1的水平,探讨MS合并AF患者心室率控制与全身凝血因子之间的关系。
本研究纳入了54例中重度MS合并AF的连续患者。静息心率<100次/分钟的患者被视为心室反应率得到控制(A组;n = 28),静息心率>100次/分钟的患者被视为心室反应率未得到控制(B组;n = 26)。
A组患者的平均二尖瓣压差和肺动脉压低于B组患者(分别为11±6与15±5,以及35±7与39±8;p均<0.05)。与A组相比,B组患者的血浆PF 1+2浓度(4.17±2.1与2.95±1.21;p<0.01)和TAT III浓度(4.61±1.75与3.12±1.01;p<0.01)升高。同样,B组患者的纤溶酶原激活物抑制剂-1水平高于A组患者(7.87±3.8与5.8±2.9;p<0.05)。心率与血浆PF 1+2和TAT水平之间存在显著相关性。多因素logistic回归分析显示,心率和平均二尖瓣压差是全身凝血激活的独立预测因素。
除了有助于改善血流动力学和缓解症状外,控制MS患者的房颤心率可使凝血激活显著下降,还可能降低血栓栓塞的发生率。